Testing the Utility of Polygenic Risk Scores for Type 2 Diabetes and Obesity in Predicting Metabolic Changes in a Prediabetic Population: An Observational Study.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Dec 2022
Historique:
received: 03 11 2022
revised: 03 12 2022
accepted: 14 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

Prediabetes is an intermediate state of hyperglycemia during which glycemic parameters are above normal levels but below the T2D threshold. T2D and its precursor prediabetes affect 6.28% and 7.3% of the world’s population, respectively. The main objective of this paper was to create and compare two polygenic risk scores (PRSs) versus changes over time (Δ) in metabolic parameters related to prediabetes and metabolic complications. The genetics of 446 prediabetic patients from the Polish Registry of Diabetes cohort were investigated. Seventeen metabolic parameters were measured and compared at baseline and after five years using statistical analysis. Subsequently, genetic polymorphisms present in patients were determined to build a T2D PRS (68 SNPs) and an obesity PRS (21 SNPs). Finally, the association among the two PRSs and the Δ of the metabolic traits was assessed. After a multiple linear regression with adjustment for age, sex, and BMI at a nominal significance of (p < 0.05) and adjustment for multiple testing, the T2D PRS was found to be positively associated with Δ fat mass (FM) (p = 0.025). The obesity PRS was positively associated with Δ FM (p = 0.023) and Δ 2 h glucose (p = 0.034). The comparison of genotype frequencies showed that AA genotype carriers of rs10838738 were significantly higher in Δ 2 h glucose and in Δ 2 h insulin. Our findings suggest that prediabetic individuals with a higher risk of developing T2D experience increased Δ FM, and those with a higher risk of obesity experience increased Δ FM and Δ two-hour postprandial glucose. The associations found in this research could be a powerful tool for identifying prediabetic individuals with an increased risk of developing T2D and obesity.

Identifiants

pubmed: 36555722
pii: ijms232416081
doi: 10.3390/ijms232416081
pmc: PMC9787993
pii:
doi:

Substances chimiques

Glucose IY9XDZ35W2

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement and the Polish Ministry of Science and Higher Education, from the financial resources for science in 2018-2023 granted for the implementation of
ID : 754432

Références

BMC Public Health. 2021 Apr 23;21(Suppl 1):381
pubmed: 33892658
PLoS Genet. 2007 Jul;3(7):e115
pubmed: 17658951
EBioMedicine. 2022 Dec;86:104383
pubmed: 36462406
Diabetes Metab Syndr Obes. 2019 Dec 24;12:2735-2743
pubmed: 31920353
Front Nutr. 2022 Apr 11;9:818263
pubmed: 35495951
Diabetologia. 2014 Feb;57(2):383-91
pubmed: 24190582
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5272-81
pubmed: 25422463
Diabetologia. 2021 Sep;64(9):2012-2025
pubmed: 34226943
J Diabetes Res. 2018 Apr 24;2018:2194604
pubmed: 29850599
World J Diabetes. 2015 Mar 15;6(2):296-303
pubmed: 25789110
J Res Med Sci. 2020 Mar 18;25:31
pubmed: 32419788
Obes Rev. 2012 Oct;13(10):923-84
pubmed: 22780564
Am J Lifestyle Med. 2015 Nov 24;12(1):4-20
pubmed: 30202378
Front Endocrinol (Lausanne). 2022 Jun 16;13:913345
pubmed: 35784577
Diabetes. 2021 Jan;70(1):293-300
pubmed: 33106254
Sci Rep. 2020 Jan 15;10(1):353
pubmed: 31941993
Eur J Nutr. 2019 Oct;58(7):2929-2941
pubmed: 30945034
Front Pediatr. 2022 Jun 24;10:917152
pubmed: 35813370
Methodist Debakey Cardiovasc J. 2018 Oct-Dec;14(4):289-297
pubmed: 30788015
J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7
pubmed: 20338491
Nat Genet. 2010 Nov;42(11):937-48
pubmed: 20935630
J Clin Med. 2020 Jul 10;9(7):
pubmed: 32664305
Int J Mol Sci. 2020 Mar 02;21(5):
pubmed: 32131491
PLoS Genet. 2020 Sep 14;16(9):e1009018
pubmed: 32925908
J Clin Endocrinol Metab. 2014 Jun;99(6):1983-92
pubmed: 24712577
Cardiovasc Diabetol. 2022 Jul 14;21(1):131
pubmed: 35836215
J Diabetes Metab Disord. 2019 Sep 14;18(2):445-451
pubmed: 31890670
Clin Diabetes Endocrinol. 2019 May 9;5:5
pubmed: 31086677
Diabetologia. 2013 Oct;56(10):2176-80
pubmed: 23979484
Antioxidants (Basel). 2022 Jun 17;11(6):
pubmed: 35740093
Int J Obes (Lond). 2018 Apr;42(4):686-695
pubmed: 29188820
Physiol Genomics. 2015 Jun;47(6):225-31
pubmed: 25805767
Obesity (Silver Spring). 2010 Jun;18(6):1212-7
pubmed: 19910938
Diabetes. 2014 Jun;63(6):2172-82
pubmed: 24520119
Clin Transl Med. 2022 Aug;12(8):e1009
pubmed: 35968930
Medicine (Abingdon). 2010 Nov 1;38(11):597-601
pubmed: 21151710
Curr Protoc Hum Genet. 2016 Oct 11;91:1.29.1-1.29.9
pubmed: 27727440
J Biomed Res. 2015 Jul;29(4):285-97
pubmed: 26243515
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Genomics. 2004 Jan;83(1):153-67
pubmed: 14667819
Circulation. 2014 Oct 14;130(16):1374-82
pubmed: 25149362
Diabetes. 2022 Feb 1;71(2):275-284
pubmed: 34753799
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
PLoS One. 2021 Jun 25;16(6):e0252501
pubmed: 34170930
Am Stat. 2019;73(Suppl 1):271-280
pubmed: 31762475
Nutr Metab (Lond). 2021 Apr 22;18(1):45
pubmed: 33888141
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Nat Med. 2021 Jan;27(1):49-57
pubmed: 33398163
Front Genet. 2022 Apr 26;13:871260
pubmed: 35559025
Int J Diabetol Vasc Dis Res. 2015;Suppl 2:
pubmed: 28596980
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
J Clin Endocrinol Metab. 2011 Oct;96(10):E1661-5
pubmed: 21795451
Genet Med. 2017 Mar;19(3):322-329
pubmed: 27513194
J Med Genet. 2020 Nov;57(11):725-732
pubmed: 32376789
J Endocr Soc. 2020 Nov 27;5(2):bvaa164
pubmed: 33381668
BMC Genet. 2017 Dec 16;18(1):115
pubmed: 29246113
Diabet Med. 2012 Jul;29(7):e62-6
pubmed: 22443470
Nat Protoc. 2020 Sep;15(9):2759-2772
pubmed: 32709988

Auteurs

Felipe Padilla-Martinez (F)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Łukasz Szczerbiński (Ł)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.
Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland.

Anna Citko (A)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Marcin Czajkowski (M)

Faculty of Computer Science, Bialystok University of Technology, Wiejska 45a, 15-351 Bialystok, Poland.

Paulina Konopka (P)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Adam Paszko (A)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Natalia Wawrusiewicz-Kurylonek (N)

Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland.
Department of Clinical Genetics, Medical University of Bialystok, 15-276 Bialystok, Poland.

Maria Górska (M)

Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland.

Adam Kretowski (A)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.
Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH